- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Phlogenzym is a drug of new generation, consisting of a combination of highly active proteolytic enzymes (enzymes) of plant and animal origin - bromelain and trypsin in combination with rutin. In combination, enzymes have a pleiotropic (multiple) effect, possessing a variety of pharmacological effects on pathophysiological and biochemical processes. The drug enzymes realize their healing effects through anti-inflammatory, immunomodulatory, antiplatelet, fibrinolytic, thrombolytic, antiedematous and secondary analgesic action. The pills of the drug, covered with an enteric-coated shell, transiently pass the upper GI tracts, without injuring the stomach, are absorbed in the small intestine by resorption of intact molecules (endocytosis, pinocytosis). The proteases of the drug, by binding to transport proteins of the blood (α-2-macroglobulin and α-1-antitrypsin), form a reversible protease-antiprotease complex, in which the antigenic determinants of exogenous proteases of the drug are masked, which prevents allergic reactions. As a result of the formation of a complex with antiprotease enzymes (α-2-macroglobulin), it passes into the active form, which performs the function of an extracellular regulator of proinflammatory cytokines and growth factors, carrying out their transfer, clearance and elimination.
The formation of the active complex protease-antiprotease allows you to safely move proteolytic enzymes along the vascular bed to the site of inflammation and to the site of injury, regardless of the place of localization in the body. The complex retains and slows down the elimination of proteolytic enzymes of the drug from the body, increases the time of their circulation in the vascular bed and, accordingly, the therapeutic effect. Getting into the center of inflammation and wounds, proteolytic enzymes break down (hydrolyze) damaged proteins, tissues and eliminate (remove) cellular debris (detritus), helping to accelerate the cleansing and healing of wounds.
The drug has a positive effect on the course of the inflammatory process, modulates the protective reactions of the body, which contributes to the physiological course of inflammation at different stages. Proteolytic enzymes of the drug accelerate the decay of inflammatory mediators, break down immune complexes and membrane deposits, increase the activity of phagocytes, natural killer cells, stimulate interferonogenesis. The proteases of the drug reduce the level of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, INF-γ, TNF-α) and help increase the production of anti-inflammatory cytokines (including IL-4, IL-10), regulate the level Ig and blood antibodies. The enzymes of the drug limit the pathological manifestations of autoimmune and immunocomplex processes, restore the body's immunological reactivity.
The proteases of the drug reduce the level of transforming growth factor β, the increase of which leads to excessive scarring. Proteolytic enzymes have a regulatory effect on the synchronization of the formation of the basement membrane (laminin), the modulation of the wound process and the expression of angiogenesis factors (vasculoendothelial growth factor, fibroblast growth factor and a number of other factors). Thus, the enzymes of the drug contribute to the improvement of reparative processes, the prevention of the formation of hypertrophic and keloid scars, the development of adhesive disease after surgical interventions on the abdominal cavity.
The drug's enzymes break down and remove damaged tissues, accelerate the resorption of hematomas and edema by normalizing the permeability of the vascular walls, reducing the infiltration of interstitium with plasma proteins, increasing the elimination of protein detritus and fibrin deposits, improving microcirculation and trophic processes in the damage zone.Optimization of proteolytic enzymes of the inflammatory process by reducing oncotic pressure and swelling of tissues, reducing pressure on nerve endings, eliminating ischemia and normalizing microcirculation, direct proteolysis of inflammatory mediators allows proteases to have a secondary analgesic effect. At the same time, proteolytic enzymes stimulate the healing and repair processes, reduce the risk of thromboembolic complications during prolonged immobilization, and prevent the development of trophic disorders and purulent complications.
Enzymes of the drug have a positive effect on improving microcirculation, increasing the delivery of oxygen and nutrients to the wound, reducing inflammation in the focus of damage, maintaining the physiological process of regeneration and accelerating the recovery of the function of organs and tissues.
The drug improves the rheological properties of blood (viscosity and fluidity) due to the positive impact on the functional state of blood cells and the vascular wall, plasticity (deformability) of erythrocytes, stabilization of endothelium permeability, increase in fibrinolytic activity of blood serum, decrease in density of adhesive molecules, decrease aggregation (coalescence) of platelets .
Proteolytic enzymes reduce the number of activated forms of platelets (spheroechnocytes) and micro- and macroaggregates, i.e. reducing the risk of blood clots in the vessels, and at the same time participate in the lysis of the formed blood clots. Proteolytic enzymes reduce the level of atherogenic lipids, helping to increase HDL, reduce the risk of atherosclerosis and vascular disorders.
The drug improves the blood supply to the bronchi and lung tissue in chronic diseases of the respiratory tract, including caused by smoking, improves the viscous properties of bronchial secretions, the function of the ciliated epithelium, restores the drainage function of the bronchi, dilutes the sputum, which facilitates breathing and reduces cough.
Proteolytic enzymes of the drug increase the effectiveness of antibiotics, while reducing the undesirable effects of antibiotic therapy (dysbiosis, irritable bowel syndrome). Proteases improve the splitting of substrates, optimize the balance of the microbiota, contribute to the restoration of the intestinal endoecology.
In the treatment and prevention of the following diseases and conditions:
- surgery - postoperative recovery and rehabilitation of patients (improvement of reparative processes and regeneration), postoperative purulent-inflammatory complications, preventing the development of adhesive disease and the formation of keloid scar, reducing the risk of thromboembolic complications during prolonged immobilization;
- traumatology - bone fractures, damage to tendons and ligaments, bruises and hematomas of soft tissues, sports injuries, burns, improved integration of endoprostheses, osteosynthesis;
- angiology - acute deep vein thrombosis, superficial vein thrombophlebitis, post-thrombotic disease, arterial atherosclerosis of the lower limbs and other chronic angiopathies, microcirculation disorders, lymphatic edema (lymphedema);
- urology - acute and chronic inflammation of the urogenital tract (cystitis, urethritis, cystopielitis, prostatitis);
- gynecology - acute and chronic inflammatory diseases of the pelvic organs (adnexitis, salpingo-oophoritis), vascular complications of menopause, reducing the frequency and severity of complications of hormone replacement therapy;
- cardiology - CHD, prevention of strokes, reducing the risk of vascular accidents and recurrent heart attacks;
- gastroenterology - Hepatitis;
- rheumatology - rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, rheumatic lesions of soft tissues;
- neurology - Ischemic stroke, multiple sclerosis;
- pulmonology - pneumonia, chronic obstructive pulmonary disease;
- dentistry - prevention of complications in the postoperative period in the extraction of teeth, purulent-inflammatory diseases of the maxillofacial area, rehabilitation and recovery after surgical interventions on the maxillofacial area, improving the integration of implants, osteosynthesis.
1 enteric coated tablet contains:
active substances: Bromelain 450 U (FIP), trypsin 1440 U (FIP) (24 μkat), rutin (rutoside) 100 mg,
Excipients: lactose monohydrate - 148.58 mg; corn starch - 24 mg; magnesium stearate - 12.72 mg; stearic acid - 11.28 mg; purified water - 6.6 mg; colloidal silicon dioxide - 6.36 mg; talc - 2.46 mg,
shell: methacrylic acid and methyl methacrylate copolymer (1: 1) - 11.89 mg; macrogol 6000 - 0.67 mg; talc - 4.08 mg; triethyl citrate - 1.2 mg; vanillin - 0.15 mg,
No customer reviews for the moment.
Dosage and Administration
Inside on 1 tablet (without chewing, washing down with a small amount of liquid) 2 times a day, whenever possible, at the same time (in the morning and in the evening). The duration of treatment is determined by the doctor.
Allergic reactions to the components of the drug. In rare cases, the appearance of pain in the epigastric region and an increase in body weight.
Hypersensitivity to the drug, estrogen-dependent tumors.
Carefully: abnormal liver function, epilepsy, diseases and injuries of the brain (use is possible only after consulting a doctor).
Without consultation of the doctor, the drug should not be taken for more than 3 months.
When changing the nature of the menstrual cycle, as well as with prolonged or other re-emerging complaints, you should contact the doctor.
When pregnancy occurs, you must stop taking the drug and consult a doctor.
Impact on the ability to drive vehicles and other mechanisms that require high concentration of attention
The drug in recommended doses does not affect the ability to drive a car and work with cars.
Symptoms: in case of accidental use of the drug in doses significantly higher than recommended, dyspepsia, gastralgia, and impaired liver function may occur.
Treatment: symptomatic. Due to the possibility of overdose, it is not recommended to take the extract with other preparations containing cimicifugu.
- Brand name: Phlogenzym
- Active ingredient: Trypsin, Rutozid, Bromelain